Michael Ackermann has shown a strong commitment to Tarsus Pharmaceuticals with notable insider trading activities. His holdings peaked at around $51.62 million in January 2021, showcasing his significant investment in the company. Over the months, these holdings varied quite a...

Michael Ackermann has shown a strong commitment to Tarsus Pharmaceuticals with notable insider trading activities. His holdings peaked at around $51.62 million in January 2021, showcasing his significant investment in the company. Over the months, these holdings varied quite a bit, indicating fluctuations based on the company's stock performance. For instance, in November 2020, his holdings were valued at $28.36 million, which climbed to $45.33 million by December of the same year. This fluctuation shows Ackermann's belief in Tarsus and its potential for growth. As of now, his holdings reflect continued involvement and confidence in the company's future trajectory.